Research
Hormonal
Semaglutide would avert 32,087 obesity cases per 100,000 individuals over a lifetime.
Semaglutide is effective in reducing obesity cases, suggesting its potential use in clinical practice.
StrongSupportsmedium confidence
Semaglutide would avert 32 087 cases (95% UI, 31 292-32 882) per 100 000 individuals.
Why this rating
Based on a lifetime cost-effectiveness analysis using a validated model.
Source
Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults
Jennifer H. Hwang et al. · JAMA Health Forum · 2025
other · n=4823Cited 50×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →